Integrative multi-omics analysis uncovers tumor-immune-gut axis influencing immunotherapy outcomes in ovarian cancer

HIGHLIGHTS

• What: The authors show increased T and B cell clusters and distinct microbial patterns with amino_acid and lipid metabolism are linked to exceptional clinical responses. No participants in this study had previous exposure to ICB as this treatment is only approved for patients with microsatellite instability (MSI-H), mismatch repair deficiency (dMMR), or high mutational burden (TMB-H)15, which is only found in ~3% of the OC patient population16. This suggests that the approach provides a compelling new treatment strategy for recurrent OC and the NCCN Ovarian Expert Guideline Panel has now listed it on the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.